This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
1rhm
From Proteopedia
OCA (Talk | contribs)
(New page: 200px<br /> <applet load="1rhm" size="450" color="white" frame="true" align="right" spinBox="true" caption="1rhm, resolution 2.50Å" /> '''CRYSTAL STRUCTURE O...)
Next diff →
Revision as of 16:57, 12 November 2007
|
CRYSTAL STRUCTURE OF THE COMPLEX OF CASPASE-3 WITH A NICOTINIC ACID ALDEHYDE INHIBITOR
Overview
Caspases are cysteine proteases that specifically cleave Asp-Xxx bonds., They are key agents in inflammation and apoptosis and are attractive, targets for therapy against inflammation, neurodegeneration, ischemia, and, cancer. Many caspase structures are known, but most involve either peptide, or protein inhibitors, unattractive candidates for drug development. We, present seven crystal structures of inhibited caspase-3 that illustrate, several approaches to reducing the peptidyl characteristics of the, inhibitors while maintaining their potency and selectivity. The inhibitors, reduce the peptidyl nature of inhibitors while preserving binding potency, by (1). exploiting a hydrophobic binding site C-terminal to the cleavage, site, (2). replacing the negatively charged aspartyl residue at P4 with, neutral groups, and (3). using a peptidomimetic 5,6,7-tricyclic system or, a pyrazinone at P2-P3. In addition, we have found that two nicotinic acid, aldehydes induce a significant conformational change in the S2 and S3, subsites of caspase-3, revealing an unexpected binding mode. These results, advance the search for caspase-directed drugs by revealing how, unacceptable molecular features can be removed without loss of potency.
About this Structure
1RHM is a Protein complex structure of sequences from Homo sapiens with NA4 as ligand. Full crystallographic information is available from OCA.
Reference
Reducing the peptidyl features of caspase-3 inhibitors: a structural analysis., Becker JW, Rotonda J, Soisson SM, Aspiotis R, Bayly C, Francoeur S, Gallant M, Garcia-Calvo M, Giroux A, Grimm E, Han Y, McKay D, Nicholson DW, Peterson E, Renaud J, Roy S, Thornberry N, Zamboni R, J Med Chem. 2004 May 6;47(10):2466-74. PMID:15115390
Page seeded by OCA on Mon Nov 12 19:03:53 2007
